In life sciences manufacturing, maintaining a state of control for equipment is not optional—it’s a regulatory and operational imperative. But traditional calendar-based calibration and maintenance programs often apply the same level of scrutiny to all assets, regardless of their impact on product quality, patient safety, or compliance. This results in over-maintenance of low-risk assets and underutilization of valuable resources.
A risk-based approach offers a smarter, more strategic alternative. By aligning activities with asset criticality and failure impact, life sciences organizations can reduce unnecessary work, improve equipment reliability, and meet regulatory expectations more efficiently.
A risk-based strategy focuses attention where it matters most—on equipment and instruments that directly impact GMP processes, product quality, and patient safety. Instead of treating all assets equally, it asks:
This method is in line with ICH Q9 (Quality Risk Management) and is increasingly expected by regulatory bodies like the FDA and EMA. It’s also central to modern quality systems and asset management frameworks such as those outlined in ISPE’s Good Practice Guides.
Risk-based calibration and maintenance is more than a trend—it’s a fundamental shift in how life sciences organizations manage compliance and reliability. By adopting a structured, data-driven approach, companies can reduce risk, improve asset performance, and operate more efficiently in a highly regulated environment.
Ready to move beyond the calendar and into smarter asset management? A risk-based strategy might be the key.
"*" indicates required fields